{"organizations": [], "uuid": "016b2be976cad36e68734a379d7cf13f3908bc00", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180123.html", "section_title": "Archive News &amp; Video for Tuesday, 23 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-macrogenics-announces-continuation/brief-macrogenics-announces-continuation-of-sophia-study-of-margetuximab-based-on-completion-of-interim-futility-analysis-idUSFWN1PI19C", "country": "US", "domain_rank": 408, "title": "BRIEF-Macrogenics Announces Continuation Of Sophia Study Of Margetuximab Based On Completion Of Interim Futility Analysis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.378, "site_type": "news", "published": "2018-01-24T06:09:00.000+02:00", "replies_count": 0, "uuid": "016b2be976cad36e68734a379d7cf13f3908bc00"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-macrogenics-announces-continuation/brief-macrogenics-announces-continuation-of-sophia-study-of-margetuximab-based-on-completion-of-interim-futility-analysis-idUSFWN1PI19C", "ord_in_thread": 0, "title": "BRIEF-Macrogenics Announces Continuation Of Sophia Study Of Margetuximab Based On Completion Of Interim Futility Analysis", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "macrogenics inc", "sentiment": "negative"}, {"name": "sophia study of margetuximab based on completion of interim futility analysis", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "sophia", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 23 (Reuters) - Macrogenics Inc:\n* MACROGENICS ANNOUNCES CONTINUATION OF SOPHIA STUDY OF MARGETUXIMAB BASED ON COMPLETION OF INTERIM FUTILITY ANALYSIS\n* MACROGENICS INC - U.S. FDA HAS GRANTED FAST TRACK DESIGNATION FOR INVESTIGATION OF MARGETUXIMAB\n* MACROGENICS - GRANTED FAST TRACK DESIGNATION FOR INVESTIGATION OF MARGETUXIMAB FOR TREATMENT OF PATIENTS WITH METASTATIC/ LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER\n* MACROGENICS INC - ANNOUNCED COMPLETION OF A PRE-PLANNED INTERIM FUTILITY ANALYSIS OF PHASE 3 SOPHIA TRIAL\n* MACROGENICS INC - AN INDEPENDENT DATA SAFETY MONITORING COMMITTEE (DSMC) HAS RECOMMENDED THAT SOPHIA STUDY CONTINUE AS PLANNED WITHOUT MODIFICATION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-24T06:09:00.000+02:00", "crawled": "2018-01-24T15:52:14.005+02:00", "highlightTitle": ""}